An Unusual Case of Drug-Induced Thrombocytopenia

被引:4
|
作者
Wang, Shiyu [1 ]
Sawalha, Khalid [1 ]
Khan, Atif [1 ]
机构
[1] White River Hlth Syst, Batesville, AR USA
来源
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS | 2020年 / 8卷
关键词
thrombocytopenia; tirofiban; GP IIb; IIIa antagonist; TIROFIBAN;
D O I
10.1177/2324709620947891
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drug-induced thrombocytopenia (DIT) is a differential diagnosis for consideration when acute thrombocytopenia is encountered in the outpatient or inpatient setting. The mechanism of thrombocytopenia induced by different antiplatelet therapies varies. DIT may occur due to antibody formation following the exposure to a drug, or naturally occurring preexisting antibodies may produce rapid-onset thrombocytopenia when a drug molecule binds to a platelet receptor inducing a conformational change thus rendering it to be an antigen target for naturally occurring antibodies. A 66-year-old female with history of hypertension presented with non-ST elevation myocardial infarction, had drug eluting stent placed in first obtuse marginal artery of left circumflex coronary artery. Started on antiplatelet medications aspirin 81 mg, ticagrelor 90 mg (which was later transitioned to clopidogrel 75 mg), as well as tirofiban 12.5 mg (for 12 hours only). Tirofiban is a GP IIb/IIIa antagonist, other drugs in this class have been documented to induce thrombocytopenia as well, but rates for tirofiban appear to be the highest, the reason is unclear. These antibodies are thought to be either naturally occurring or induced from conformational changes to GP IIb/IIIa binding site after binding to the GP IIb/IIIa receptor, binding of these drugs to the receptor precipitates an epitope much more specific for platelet surface antigens. Tirofiban and clopidogrel/ticagrelor can cause thrombocytopenia, but onset in this case is unusual: acute antibody reaction would be expected within hours, not delayed 30 hours after starting antiplatelet medication, and nonacute reaction would present 1 to 2 weeks out.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Drug-induced thrombocytopenia: a case report
    Chavez, K. Rodriguez
    Brandl, E.
    Wilfi, A.
    Tillinger, W.
    TUMORBOARD, 2016, (01): : 9 - 11
  • [2] DRUG-INDUCED THROMBOCYTOPENIA
    MERVYN, A
    SAHUD, MD
    SHEILAFLAHERTY, BS
    PATHOLOGIE BIOLOGIE, 1994, 42 (08): : 806 - 806
  • [3] Idiosyncratic drug-induced thrombocytopenia
    Serraj, K.
    Mecili, M.
    Aouni, M.
    Maaouni, A.
    Andres, E.
    REVUE DE MEDECINE INTERNE, 2009, 30 (10): : 866 - 871
  • [4] Drug-induced Immune Thrombocytopenia
    Chong, Beng H.
    Choi, Philip Young-Ill
    Khachigian, Levon
    Perdomo, Jose
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (03) : 521 - +
  • [5] Drug-Induced Immune Thrombocytopenia
    Patricia M. L. A. van den Bemt
    Ronald H. B. Meyboom
    Antoine C. G. Egberts
    Drug Safety, 2004, 27 : 1243 - 1252
  • [6] Drug-induced thrombocytopenia in a patient with colorectal cancer: A case report
    Pasquariello, Stefano
    Clavarezza, Matteo
    Piredda, Sabrina
    Foppiani, Luca
    Pesce, Giampaola
    Antonucci, Giancarlo
    De Censi, Andrea
    Mattioli, Francesca
    ONCOLOGY LETTERS, 2023, 26 (03)
  • [7] Recognition and management of drug-induced cytopenias: the example of idiosyncratic drug-induced thrombocytopenia
    Andres, Emmanuel
    Dali-Youcef, Nassim
    Serraj, Khalid
    Zimmer, Jacques
    EXPERT OPINION ON DRUG SAFETY, 2009, 8 (02) : 183 - 190
  • [8] Drug-Induced Thrombocytopenia in the Critically Ill: A Case-Control Study
    Williamson, David R.
    Lesur, Olivier
    Tetrault, Jean-Pierre
    Pilon, Danielle
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (06) : 697 - 704
  • [9] Drug-Induced Thrombocytopenia in the Coronary Care Unit
    Nicole M Patnode
    Pritesh J Gandhi
    Journal of Thrombosis and Thrombolysis, 2000, 10 : 155 - 167
  • [10] Drug-induced thrombocytopenia after anticoagulation with rivaroxaban
    Pop, Marianne K.
    Farokhi, Farhad
    Iduna, Lela
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2018, 36 (03) : 531.e1 - 531.e2